Development of technology by R&D MCQs With Answer

Introduction:

This set of MCQs on “Development of technology by R&D” is designed for M.Pharm students preparing for exams and practical roles in pharmaceutical product development and technology transfer. The questions focus on core concepts such as scale-up challenges, process optimization, Quality by Design (QbD), Design of Experiments (DoE), Process Analytical Technology (PAT), regulatory CMC requirements, validation strategies, intellectual property and risk assessment. Each question is constructed to deepen understanding of how laboratory discoveries are transformed into robust, regulatory-compliant manufacturing processes. Use these questions to assess knowledge gaps, reinforce critical thinking, and prepare for real-world technology development tasks.

Q1. What is the primary objective of R&D during the development of a new pharmaceutical technology?

• To transfer marketing responsibilities to sales
• To transform a laboratory-scale process into a robust and reproducible manufacturing process
• To reduce packaging costs only
• To prepare only regulatory submission documents

Correct Answer: To transform a laboratory-scale process into a robust and reproducible manufacturing process

Q2. Pilot-scale demonstration of a process typically corresponds to which Technology Readiness Level (TRL)?

• TRL 3 — Experimental proof of concept
• TRL 6 — Technology demonstrated in relevant environment (pilot-scale)
• TRL 9 — Actual system proven in operational environment
• TRL 1 — Basic principles observed

Correct Answer: TRL 6 — Technology demonstrated in relevant environment (pilot-scale)

Q3. Which statement best describes “technology transfer” in the pharmaceutical industry?

• The marketing handover of a product to sales representatives
• The transfer of process knowledge, documentation and responsibility to enable consistent manufacturing at another site
• The transfer of raw materials between suppliers
• The transfer of clinical trial data to regulatory authorities

Correct Answer: The transfer of process knowledge, documentation and responsibility to enable consistent manufacturing at another site

Q4. Which document typically defines objectives, scope, responsibilities and timelines for a technology transfer project?

• Master Production Record (MPR)
• Technology Transfer Plan (TTP)
• Batch Manufacturing Record (BMR)
• Certificate of Analysis (CoA)

Correct Answer: Technology Transfer Plan (TTP)

Q5. Which scale-dependent factors are most critical to address during scale-up from laboratory to pilot or commercial scale?

• Color of equipment and operator uniforms
• Heat transfer and mixing (mass transfer) characteristics
• Frequency of meetings with management
• Supplier branding of raw materials

Correct Answer: Heat transfer and mixing (mass transfer) characteristics

Q6. What is the fundamental principle of Quality by Design (QbD) in pharmaceutical development?

• Eliminate all documentation during development
• Adopt a systematic approach to product and process development based on sound science and risk management
• Delay any process understanding until after registration
• Maximize empirical batch-to-batch variability

Correct Answer: Adopt a systematic approach to product and process development based on sound science and risk management

Q7. How is Design of Experiments (DoE) most often used during process development?

• To randomly select one factor to optimize without repetition
• To systematically study the effects and interactions of multiple process variables and optimize conditions
• To replace analytical methods with visual inspection
• To eliminate statistical analysis from development

Correct Answer: To systematically study the effects and interactions of multiple process variables and optimize conditions

Q8. Which of the following analytical techniques is commonly used as a Process Analytical Technology (PAT) tool for real-time monitoring?

• Near-infrared (NIR) spectroscopy for in-line solid-state monitoring
• Traditional off-line titration only
• End-of-shelf-life microbial testing
• Final product dissolution testing performed after packaging

Correct Answer: Near-infrared (NIR) spectroscopy for in-line solid-state monitoring

Q9. What defines a Critical Quality Attribute (CQA)?

• A property of the process equipment that is irrelevant to product performance
• A physical, chemical, biological or microbiological property that should be within limits to ensure product quality, safety or efficacy
• A marketing descriptor for promotional materials
• An operator preference for production scheduling

Correct Answer: A physical, chemical, biological or microbiological property that should be within limits to ensure product quality, safety or efficacy

Q10. The main aim of process validation during scale-up is to:

• Show that the process can be performed by a single operator only
• Demonstrate that the manufacturing process consistently produces product meeting predetermined specifications at commercial scale
• Prove that the lab process is cheaper than competitors
• Replace the need for batch records

Correct Answer: Demonstrate that the manufacturing process consistently produces product meeting predetermined specifications at commercial scale

Q11. Forced degradation studies during development are primarily used to:

• Accelerate formulation of packaging materials
• Identify likely degradation pathways and develop stability-indicating analytical methods
• Shorten clinical trial duration
• Determine taste masking for oral products

Correct Answer: Identify likely degradation pathways and develop stability-indicating analytical methods

Q12. The objective of analytical method transfer during technology transfer is to:

• Ensure the receiving laboratory can perform the method with equivalent accuracy, precision and robustness
• Replace all methods with simpler visual checks
• Transfer only the SOP title without procedures
• Confirm that only one analyst can run the method

Correct Answer: Ensure the receiving laboratory can perform the method with equivalent accuracy, precision and robustness

Q13. Where in the Common Technical Document (CTD) are detailed manufacturing and control information submitted?

• Module 1 — Administrative information
• Module 3 — Quality (CMC) information
• Module 4 — Nonclinical study reports
• Module 5 — Clinical study reports

Correct Answer: Module 3 — Quality (CMC) information

Q14. What is the recommended patent strategy when a novel manufacturing technology is developed in an academic or industrial R&D setting?

• Publicly disclose the technology first and file the patent later
• File a patent or provisional application before any public disclosure to preserve patent rights
• Never file patents; rely only on trade secrets
• Only register trademarks for the technology

Correct Answer: File a patent or provisional application before any public disclosure to preserve patent rights

Q15. Which risk-assessment tool is commonly used in technology transfer to identify potential failure modes and controls?

• SWOT analysis exclusively for marketing
• Failure Modes and Effects Analysis (FMEA)
• Only qualitative brainstorming without documentation
• ISO 9000 certification review only

Correct Answer: Failure Modes and Effects Analysis (FMEA)

Q16. A pilot plant is primarily used during development to:

• Produce only clinical trial placebos
• Reproduce industrial conditions to reveal scale-dependent issues and validate process parameters
• Replace the need for process documentation
• Perform final batch release testing

Correct Answer: Reproduce industrial conditions to reveal scale-dependent issues and validate process parameters

Q17. During lyophilization cycle development for a freeze-dried product, which thermal parameter is most critical to determine?

• Operator shoe size
• Collapse temperature (or Tg’ of the formulation)
• Ambient humidity outside the freeze-dryer room only
• Color of vials used

Correct Answer: Collapse temperature (or Tg’ of the formulation)

Q18. Regulatory guidance commonly suggests how many consecutive successful validation batches to demonstrate commercial-scale reproducibility?

• One batch is sufficient
• Three consecutive successful commercial-scale batches
• Ten consecutive batches always required
• No batches are needed if pilot data exist

Correct Answer: Three consecutive successful commercial-scale batches

Q19. What is a typical role of a Contract Manufacturing Organization (CMO) in technology transfer?

• Only provide warehousing services without technical input
• Implement the transferred process, conduct scale-up runs and support validation under agreed quality and regulatory requirements
• Replace the sponsor’s regulatory filings entirely
• Design clinical protocols for the sponsor

Correct Answer: Implement the transferred process, conduct scale-up runs and support validation under agreed quality and regulatory requirements

Q20. What does a “Freedom to Operate” (FTO) analysis assess during technology development?

• The product’s dissolution profile only
• Potential patent and intellectual property barriers that could prevent commercialization
• The nutritional content of excipients
• Only the safety profile of the API

Correct Answer: Potential patent and intellectual property barriers that could prevent commercialization

Download